KMTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Kestra Medical Technologies Ltd (KMTS) is not a strong buy for a beginner, long-term investor at this time. While the company shows strong revenue growth and improving financial metrics, the lack of significant trading signals, neutral sentiment from hedge funds and insiders, and bearish moving averages suggest that the current price does not present an optimal entry point. Additionally, the absence of recent news or catalysts limits the immediate upside potential.
The MACD histogram is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 62.965, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its R1 resistance level of 20.59, with key support at 19.23. Overall, the technical indicators suggest a mixed trend with no strong buy signal.
Analysts maintain a Buy rating despite a slight reduction in the price target.
Bearish moving averages, lack of significant hedge fund or insider trading activity, and no recent news or event-driven catalysts. Additionally, the company remains unprofitable with a net income of -$32.79M.
In Q2 2026, Kestra Medical reported a revenue increase of 53.40% YoY to $22.57M. Net income improved by 38.39% YoY but remains negative at -$32.79M. EPS increased by 33.33% YoY to -0.64, and gross margin rose to 50.63%, up 27.76% YoY. While growth trends are positive, profitability remains a concern.
BTIG recently lowered the price target from $32 to $30 but maintained a Buy rating. The adjustment reflects updates related to CMS's proposed rule for FY27 inpatient prospective payment systems, which could impact new technology add-on payments.
